Schrodinger (SDGR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.42
- Estimate
- -$0.67
- Surprise
- +37.9%
- Revenue (period 2026-06-30)
- $58.9M
- Score today
- 4.3/10
Revenue source: xbrl.
How the report landed
Schrodinger (SDGR) reported a narrower loss than forecast — diluted EPS of -$0.42 against the -$0.67 estimate (a 37.9% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SDGR Sell at 4.3/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +37.9% surprise compares with a -12.1% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Target reached (-2.0% upside)
- Quality below floor (3.2 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (12 sells, 4.05% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.02
- Price target
- $20.97
- Stop
- $17.69
- Upside to target
- +10.3%
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
SDGR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $1.42B
- P/E (fwd)
- -14.1
- 52-week range
- $10.95–$23.02
- Off 52-week high
- 17.4%
- RSI (14)
- 46
- Volume vs avg
- 0.50×
- Score today
- 4.3/10